Brief: Kintor Pharmaceutical Says Proxalutamide Clinical Trial As COVID-19 Treatment Saw First Patient Enrolment In Brazil
21/08/2020 14:45
Aug 21 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* KINTOR PHARMACEUTICAL UPDATES ON DEAL BETWEEN APPLIED
BIOLOGY &
CO TO CONDUCT RESEARCH FOR PROXALUTAMIDE AS TREATMENT FOR
CORONAVIRUS DISEASE
* ON 20 AUGUST, CLINICAL TRIAL RECORDED FIRST PATIENT
ENROLMENT IN
BRAZIL
* ESTIMATED THAT CLINICAL TRIAL WILL COMPLETE BY END OF
JANUARY
2021
Source text for Eikon: urn:newsml:reuters.com:*:nHKSc3lHJb
Further company coverage: 9939.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint